Related Experiment Video
Updated: Aug 26, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Adjusting Survival Curves to Incorporate External Evidence: A Simplified Approach without Patient-Level Data
David McConnell1,2, Arthur White1,3, Felicity Lamrock1,4
1National Centre for Pharmacoeconomics, St James's Hospital, Dublin, Ireland.
Introduction:
Cost-effectiveness modelling often requires the extrapolation of survival data from clinical trials. The choice of extrapolation method is often uncertain and can have a profound effect on the results. We propose an approach that incorporates external evidence (eg, from published studies, registries, or elicited clinical opinion) into the extrapolation process to reduce uncertainty. This method can be applied to adjust previously fitted parametric curves as a secondary analysis, without access to the underlying patient-level data. Adjusted curves can be easily exported and used in spreadsheet-based models.
Methods:
Standard parametric survival curves are fitted to time-to-event data using maximum likelihood estimation (MLE). These are combined with external evidence on expected cohort-level survival at a future time point(s), formulated as a probability distribution, to generate adjusted survival curves that simultaneously incorporate both observed data and external evidence. Parameter estimation uses importance sampling and multivariate normal approximations of the likelihood. We apply our method to a case study of survival extrapolation from immuno-oncology.
Results:
Our method resulted in extrapolated survival predictions that were more closely aligned with the external evidence compared with the standard (MLE-based) approach. The incorporation of external evidence decreased the between-distribution variance (reduced structural uncertainty) and for most distributions also decreased within-distribution variance (reduced parametric uncertainty).
Conclusion:
Our extrapolation method can reduce uncertainty when valid external evidence is available. Only MLE-based parameter estimates are required to implement our method; thus, secondary model users such as health technology assessment bodies can adjust survival extrapolations from existing cost-effectiveness models without access to patient-level data. Implementation is straightforward and computationally efficient, and outputs are easily incorporated into existing cost-effectiveness models.
Related Concept Videos
Kaplan-Meier Approach
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Comparing the Survival Analysis of Two or More Groups
Assumptions of Survival Analysis
Cancer Survival Analysis
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

